Search results for "HPV vaccine"
showing 10 items of 14 documents
Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
2021
AbstractThe prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the …
Infezione orale da Human papillomavirus: dalla verruca al carcinoma orale. Epidemiologia, clinica, prevenzione e terapia
2015
Riasunto Obiettivi Prendere in esame l’epidemiologia e le manifestazioni cliniche dell’infezione orale da Human papillomavirus (HPV), con particolare attenzione alle lesioni con potenziale oncologico maligno. Materiali e metodi E stata condotta una revisione sistematica della letteratura finalizzata a descrivere lo stato dell’arte in merito all’infezione da HPV nella mucosa orofaringea e alle relative modalita di trasmissione del virus con particolare riferimento alla possibile contemporanea infezione in sedi anatomiche multiple. Vengono approfonditi gli aspetti riguardanti la prevenzione e il controllo dell’infezione mediante la somministrazione di vaccini e lo svolgimento di campagne cono…
15-25 gadīgo zināšanas par cilvēka papilomas vīrusu
2022
Vispārīga informācija:Cilvēka papilomas vīruss (HPV) ir viens no visizplatītākā seksuāli transmisīvā slimība visā pasaulē. Infekcijas sekas var būt maksts, vulvas, dzemdes kakla, dzimumlocekļa, anālā rajona, mutes dobuma un rīkles vēzis, kā arī kārpas dzimumorgānu rajonā. Infekciju veicinošie faktori ir dzimumakts bez prezervatīva, liels dzimumpartneru skaits, agrīns pirmais dzimumakts un smēķēšana. Vissvarīgākais primārais profilakses pasākums ir vakcinācija pret HPV. Mērķis:Darba objektīvais mērķis ir novērtēt 15-25 gadi vecu cilvēku zināšanas un izpratni par HPV un atrast ietekmējošos faktorus, lai nākotnē radītu mērķtiecīgāku izskaidrošanu. Materiāli un metodes:200 dalībnieki aizpildīja…
Facilitators and barriers HPV unvaccinated girls after 5 years of program implementation
2014
Understanding perceptions and characteristics of human papillomavirus (HPV) vaccinated and non-vaccinated girls can inform communication activities and vaccine delivery strategies. The purpose of this study was to evaluate knowledge and factors associated with HPV unvaccinated girls after five years of vaccination program implementation in Sicily, an Italian region with low vaccination coverage (<50.0%). A cross-sectional study was conducted through a questionnaire designed to assess knowledge and vaccination status of girls of 1997, 1998, 1999, and 2000 birth cohorts. The sample consisted of 350 girls who attended three high schools. Multivariable logistic regression analysis was conducted…
Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure
2006
The potential of human papillomavirus (HPV) vaccines will only be realized if the vaccine candidates under development prove to be safe and effective and can be consistently produced to define quality standards. Whilst the responsibility for delivering a safe and effective product rests with the vaccine producer, a vaccine requires a license to allow it to be placed on the market. Licensure is based on an evaluation of the safety and efficacy profile of a vaccine candidate by national regulatory authorities, ideally on the basis of internationally agreed, science-based specifications and procedures. For vaccines, these international specifications are developed by the World Health Organizat…
Human papilloma virus infection and vaccination: Pre-post intervention analysis on knowledge, attitudes and willingness to vaccinate among preadolesc…
2020
In recent years, vaccination coverage rates against Human Papilloma Virus (HPV) in Europe have shown a decreasing trend and remain below the required standard. The present study aims to assess knowledge and attitudes regarding HPV infection and vaccination among a representative sample of preadolescents of Palermo, Italy. A survey was carried out throughout two questionnaires, before and after carrying out an educational intervention scheduled during school hours. A total of 1702 students attending first-grade secondary schools of the province of Palermo were enrolled (response rate 68.9%). Students attending third classes (adj OR = 1.18
Vaccination against HPV-Associated Neoplasias
2014
Neoplasias associated with anogenital human papilloma viruses (HPV) are characterised by high patient morbidity and mortality and by appreciable limitations in the patientʼs quality of life. Each year 530,000 women worldwide and 4800 women in Germany develop cervical cancer 1, 2. Biomolecular and epidemiological studies carried out in the past 25 years have demonstrated causal link between persisting infections with HPV 16 and HPV 18 and at least 11 other so-called high-risk HPVs (HR-HPVs) and the development of cervical cancer and its precursor lesions (so-called dysplasias or, respectively, cervical intraepithelial neoplasias – CIN). HPV 16, HPV 18 and other HR-HPVs are also the causes of…
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.
2013
Contribution over time of human papillomavirus (HPV) types in human cancers has been poorly documented. Such data is fundamental to measure current HPV vaccines impact in the years to come. We estimated the HPV type-specific distribution in a large international series of invasive cervical cancer (ICC) over 70 years prior to vaccination. Paraffin embedded ICC cases diagnosed between 1940 and 2007 were retrieved from eleven countries in Central-South America, Asia and Europe. Included countries reported to have low-medium cervical cancer screening uptake. Information on age at and year of diagnosis was collected from medical records. After histological confirmation, HPV DNA detection was per…
Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention
2011
Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …
Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…
2017
ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…